Elevation Oncology Inc - Asset Resilience Ratio
Elevation Oncology Inc (ELEV) has an Asset Resilience Ratio of 24.52% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Elevation Oncology Inc's Asset Resilience Ratio has changed over time. Check Elevation Oncology Inc (ELEV) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Elevation Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Elevation Oncology Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.16 Million | 24.52% |
| Total Liquid Assets | $20.16 Million | 24.52% |
Asset Resilience Insights
- Good Liquidity Position: Elevation Oncology Inc maintains a healthy 24.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Elevation Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Elevation Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Elevation Oncology Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Elevation Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 45.72% | $43.72 Million | $95.63 Million | +7.72pp |
| 2023-12-31 | 38.00% | $33.85 Million | $89.09 Million | -9.12pp |
| 2022-12-31 | 47.11% | $44.36 Million | $94.16 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $149.49 Million | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more